Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough
Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
Novartis International AG /
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA...
LONDON, July 28, 2016 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN;
("LivaNova" or the "Company"), a market-leading medical technology and
innovation company, today announced that Andrea L. Saia has been elected to...
WASHINGTON (dpa-AFX) - Apricus Biosciences, Inc. (APRI), Monday said it has
agreed with Sandoz to mutually terminate license agreement and to expand its
exclusive distribution agreement with Ferring Pharmaceuticals, for the